126
Participants
Start Date
December 31, 2013
Primary Completion Date
December 31, 2016
Study Completion Date
March 31, 2017
novel kit for the detection of PAMG-1
The novel kit for the detection of PAMG-1 is a diagnostic device employing monoclonal antibodies that detect Placental α1 Microglobulin present in cervico-vaginal secretions manufactured by AmniSure® International, LLC, Boston, MA. The in vivo sensitivity detection threshold is 4ng/ml. During the test procedure, PAMG-1 from the sample sequentially binds to monoclonal antibody conjugated with labeled particles, then to monoclonal antibody immobilized on an insoluble carrier. The test requires a 30 second swab saturation in the vagina (a sterile speculum examination is not required), a 30 second active washing step whereby the swab just removed from the vagina is actively rotated in a solvent filled vial and lastly, a 5 minute waiting period from the time the swab is removed and the test strip is inserted if two testing lines do not appear sooner.
Prof. Dr. Daniel Surbek, Bern
Collaborators (1)
AmniSure International LLC
OTHER
Insel Gruppe AG, University Hospital Bern
OTHER